Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
Pharmaceutical compositions of (E)-2,4,6-trimethoxy styryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone and pharmaceutically acceptable salts thereof are described as well as methods of their use, and a dose regimen of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone, sodium salt to reduce the incidence of urothelial toxicity.
1. A method of treating a solid tumor cancer comprising administering an effective amount of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone, sodium salt to a patient in need thereof, further comprising orally administering a first dose of 840 mg approximately 1-2 hours before breakfast and a second dose of 280 mg about 6 to about 8 hours after the first dose in a fasting state, or administering a first dose of 560 mg approximately 1-2 hours before breakfast and a second dose of 280-560 mg about 6 to about 8 hours after the first dose in a fasting state.
2. The method of claim 1 , wherein said solid tumor cancer is selected from the group consisting of prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer, melanomas, glioblastoma, Kaposi's sarcoma, leiomyosarcoma, non-small cell lung cancer, colorectal cancer, and head and neck cancer.
3. The method of claim 2 , wherein said solid tumor cancer is lung cancer.
4. The method of 3 , wherein said solid tumor cancer is non-small cell lung cancer.
5. The method of claim 2 , wherein said patient is administered (E)-2,4,6trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone, sodium salt for three weeks followed by one week off and said patient is also administered azacitidine starting at day 8 for one week.